Cambridge, UK, 30th April: PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital.
A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew…
Do you as a company with a brilliant idea to solve a healthcare issue need to hire a Chief Medical Officer(CMO) at an early stage of your development?
The answer is NO, a perspective
Lets look at a typical job responsibility of a CMO
To perform this job successfully, an individual must be able to perform the following:
1) Direct the development of clinical strategies and plan to integrate compounds into the standard practice of the subject indication sometimes 2 or 3 indications.
2) Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities.
3)…
InVisionFirst®-Lung demonstrated excellent concordance with tissue profiling and detected 26% more actionable alterations thanstandard-of-care testing
Data from two prospective U.S. trials published in Journal Clinical Oncology – Precision Oncology
Research Triangle Park, NC and Cambridge, UK, April 26, 2019 -- Inivata, a leader in liquid biopsy, today published the clinical validation results and real-world utility of its InVisionFirst-Lung liquid biopsy test for use in advanced non-small cell lung cancer (NSCLC). Inivata conducted two prospective, multi-center studies in…
CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards in Laboratory Practices
Research Triangle Park, NC and Cambridge, UK, April 18, 2019 -- Inivata, a leader in liquid biopsy, today announces that it has received Accreditation from the College of American Pathologists (CAP) for its CLIA laboratory in Research Triangle Park, North Carolina. The CAP Accreditation is awarded to laboratories which meet stringent quality, accuracy and consistency requirements.
The CAP Laboratory Accreditation Program began in the early 1960s and is widely recognized as being…
16 April 2019 – Genomics England has announced today the successful completion of the first phase of its collaboration with Inivata and Thermo Fisher Scientific. This is part of a pilot project, undertaken by Genomics England in collaboration with industry, to:
• assess the suitability of circulating tumour DNA (ctDNA) samples collected by the NHS during the 100,000 Genomes Project• perform objective technology evaluation of the various market offerings in liquid biopsy• generate evidence for the potential consideration of such technology implementation in future routine healthcare for better…
Further Milestone from Janssen on NDA Approval by the US FDA of BALVERSA™ (erdafitinib) for the Treatment of Urothelial Cancer
Cambridge, UK, 12 April 2019, Astex Pharmaceuticals (Astex), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has received a milestone payment from Janssen Pharmaceutica N.V. (Janssen). This follows the United States Food and Drug Administration’s (FDA) accelerated review and approval of a Janssen New Drug Application (NDA) for…
Businesses across East Anglia are turning to placement students from the University of East Anglia (UEA) to help innovate and grow their organisations.
Increasing numbers of businesses are hosting placement students with many offering them permanent positions when they graduate.
What is a placement student and how could they benefit you? A placement is an opportunity to recruit a student to work with you and your organisation for 9 – 14 months. It’s more than just work experience or shadowing; a placement student can bring real benefits to your business. You gain an…
BILLINGHAM, England, April 11, 2019 /PRNewswire/ -- FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
The introduction of new single step cloning technology, in combination with the new Apollo X host cell line has allowed development timelines to be significantly reduced. The Apollo…
AMSBIO announces XerumFree™ - a new concept in cell culture that allows you to culture cells without the use of serum.XerumFree™ has been developed taking into account what is missing in traditional basal cell culture media to sustain growth of all cell types, which is a nutritional approach at the cellular level. Containing no animal or human derived material, XerumFree™ is a serum replacement for all cell culture practices that is chemically defined thereby avoiding lot-to-lot variations and eliminating the need for testing new batches of serum. Since XerumFree™ does not contain…
Detachin™ Cell Detachment Solution from AMSBIO is a high-performance alternative to Trypsin/EDTA for detaching adherent cells from in vitro growth vessels. Detachin™ provides rapid, gentle, and effective detachment of a wide variety of adherent cells, including primary cells, from all commercially available tissue culture plasticware.
Proven to provide a consistent, safe, and efficient method for cell detachment and dissociation, Detachin™ contains protease and collagenase activities in an isotonic, phosphate buffer solution with EDTA. It has been tested successfully on many different primary…